Clinical Trial Update: Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial assessing the safety of belimumab in people with idiopathic CD4 lymphopenia and autoantibodies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Cd4 Lymphopenia

Drugs mentioned

• BENLYSTA (belimumab)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Idiopathic CD4 Lymphopenia | Phase 1 | Status: RECRUITING